Can These Biotech Stocks Recover from an FDA Setback and a Stark 2Q Preliminary Earnings Stumble?
Finish Line Shares Fell Off a Cliff on Weak Outlook
Today’s only report was bad once again. Markit’s PMI preliminary report for September was 51.
With the ink dry on a record-breaking 2016 NBA finals, Piper Jaffray analyst Erinn Murphy weighs in on athletic retailer giants Nike Inc …
In a research report issued today, Deutsche Bank analyst Paul Trussell reiterated a Buy rating on The Finish Line (NASDAQ:FINL) with a $32 price target, …
In a research report issued today, Sterne Agee analyst Sam Poser reiterated a Neutral rating on Finish Line (NASDAQ:FINL). No price target was …
